EP1024842A2 - Implants medicaux revetus, leur procede de preparation et leur utilisation pour la prevention de restenoses - Google Patents
Implants medicaux revetus, leur procede de preparation et leur utilisation pour la prevention de restenosesInfo
- Publication number
- EP1024842A2 EP1024842A2 EP98952617A EP98952617A EP1024842A2 EP 1024842 A2 EP1024842 A2 EP 1024842A2 EP 98952617 A EP98952617 A EP 98952617A EP 98952617 A EP98952617 A EP 98952617A EP 1024842 A2 EP1024842 A2 EP 1024842A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polymer
- medical implants
- stent
- epothilone
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D175/00—Coating compositions based on polyureas or polyurethanes; Coating compositions based on derivatives of such polymers
- C09D175/04—Polyurethanes
- C09D175/08—Polyurethanes from polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Definitions
- the invention relates to agents for the production of coated, drug-delivering medical implants, e.g. Stents, the implants prepared in this way, processes for their preparation and their use for restenosis prophylaxis.
- coated, drug-delivering medical implants e.g. Stents
- Implants especially stents, are state of the art (Pschyrembel, clinical dictionary 257th edition, publisher W. de Gruyter). Stents are self-expanding endoprostheses that keep the gait open
- Enable structures in human or animal bodies e.g. vascular, esophageal, tracheal, bile duct stent. They are used as a palliative measure for narrowing due to occlusion (eg atherosclerosis) or external pressure (eg for tumors).
- Radioactive stents are used, for example, after vascular surgery or interventional radiological interventions (eg balloon angioplasty) for prophylaxis of restenosis.
- a stent is known from international patent application WO 94/13268, which gradually releases an active substance in the body.
- a polymer composition is known from US Pat. No. 5,599,552 which can gel in the body. In solid form, it represents an implant that can gradually release an active ingredient.
- the object of the present invention is therefore to provide medical implants which are better tolerated than conventional medical implants.
- the surface of the medical implants is coated with a polymer into which at least one active ingredient based on the epothilone base, e.g. Epothilon A or B or a derivative of epothilone, as well as possibly other active substances, e.g. thrombosis-preventing substances and / or estrogens and / or corticosteroids are incorporated.
- Epothilone and its synthesis are known from the literature (Höfle et al., Angew. Chem. 108: 1 671 -3 (1 996), Schinzer et al., Angew. Chem. 1 09: 543-4 (1997)).
- the active substance epothilone can also be applied directly to the medical implant without a polymer.
- the device according to the invention thus consists of the medical implant, possibly of a polymer on the surface of the implant and at least one active ingredient from the class of the epothilones.
- the invention also relates to devices, substances, solutions and containers for the coating of implants according to the invention, for example in the form of a kit. Such kits can be used by the physician on site for the coating of selected implants.
- the commercially available implants can be used as the base body, for the stents e.g. a Wiktor stent, a Strecker stent or a Palmaz-Schatz stent.
- suitable polymers are polyurethanes, polylactides, mixed polylactide glycolides or other polymers described in the literature.
- the implants according to the invention - described with the aid of stents - can be produced by way of example as follows:
- An uncoated stent is first coated with a polymer (e.g. a polyurethane, obtainable from the reaction of an amphiphilic polyether, diphenyimethane-4-4'-diisocyanate and butanediol).
- a polymer e.g. a polyurethane, obtainable from the reaction of an amphiphilic polyether, diphenyimethane-4-4'-diisocyanate and butanediol.
- a solvent e.g. chloroform
- Active ingredient epothilone
- the same solvent for example chloroform or ethyl acetate
- Another active ingredient can be applied to epothilone derivative.
- active ingredients are antithrombotic drugs, e.g. Iloprost, estrogens such as ethinyl estradiol or corticoids such as Dexamethasone, Fluocortolon, Difluorcortolon or their esters.
- An uncoated stent can first be coated with a polymer (e.g. a polyurethane, obtainable from the reaction of an amphiphilic polyether, diphenylmethane-4-4'-diisocyanate and butanediol). This polymer is modified so that it is on the surface
- Cyclodextrin carries.
- the polymer is dissolved in a solvent (e.g. chloroform) and the stent is immersed in the polymer solution. After the stent has been removed from the polymer solution, it is dried in a drying chamber at room temperature.
- the "activation" of the stent now takes place by immersing the modified stent in an aqueous solution of epothilone. The active ingredient is incorporated into the cyclodextrin. The stent is now ready for use.
- the implants according to the invention achieve the task described in the introduction.
- the implants according to the invention are physiologically well tolerated.
- the particular advantage of the implants according to the invention is that the physician can select a stent according to his needs on site and then activate the selected stent by the described method.
- the few substances and solutions required for this can be delivered prepared accordingly, so that the corresponding medical practitioner only has to immerse the uncoated stent in the given order in the individual solutions.
- the invention thus also relates to those substances, solutions and preparations (kits) and containers prepared for the method according to the invention.
- the polymer used is polyurethane, which can be obtained as a chain extender by reacting an amphiphilic polyether, diphenylmethane-4,4'-diisocyanate and butanediol.
- the stents are coated by immersing them in a 5% chloroform solution of the polymer. Then they are allowed to dry in a clean room drying chamber at room temperature. The average layer thickness is 20 ⁇ m.
- Epothilon A is coated by immersing the polymer-coated stent in an aqueous solution of Epothilon A (0.5 mg / ml). After drying, the stent is ready for use.
- the coating of the stent with the polymer and the subsequent coating with epothilone A is carried out as described in Example 1. However, the stent is now alternately immersed in a solution with the polymer and - after drying - in an aqueous solution of Epothilon A. This creates a multi-layer structure. The amount of active ingredient incorporated can be controlled via the number of epothilone-containing layers. The stent is implanted after the last drying cycle.
- the coating is carried out as described in Example 2. However, the stent is now alternately immersed in a solution with the polymer and - each after drying - in an aqueous solution of epothilone A or lloprost or a solution of an estrogen derivative or corticoid in chloroform.
- the order of the coating materials can be varied. This creates a multi-layer structure. The amount of active ingredient incorporated can be controlled via the number of the respective layers.
- the stent is implanted after the last drying cycle.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
L'invention concerne des agents pour la préparation d'implants médicaux revêtus libérant des principes actifs, par exemple des extenseurs, les implants ainsi préparés, leur procédé de préparation et leur utilisation pour la prévention de resténoses.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19744135A DE19744135C1 (de) | 1997-09-29 | 1997-09-29 | Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe |
DE19744135 | 1997-09-29 | ||
PCT/EP1998/006019 WO1999016416A2 (fr) | 1997-09-29 | 1998-09-24 | Implants medicaux revetus, leur procede de preparation et leur utilisation pour la prevention de restenoses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1024842A2 true EP1024842A2 (fr) | 2000-08-09 |
Family
ID=7844759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98952617A Withdrawn EP1024842A2 (fr) | 1997-09-29 | 1998-09-24 | Implants medicaux revetus, leur procede de preparation et leur utilisation pour la prevention de restenoses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1024842A2 (fr) |
JP (1) | JP2001517543A (fr) |
AU (1) | AU1025199A (fr) |
DE (1) | DE19744135C1 (fr) |
WO (1) | WO1999016416A2 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69734362T2 (de) | 1996-12-03 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
JP5140220B2 (ja) | 1999-05-27 | 2013-02-06 | バイオコンパテイブルズ・ユーケイ・リミテツド | 局所的な薬剤送達 |
ATE350077T1 (de) | 2000-04-11 | 2007-01-15 | Polyzenix Gmbh | Verwendung von folien aus poly-tri-fluor- ethoxypolyphosphazenen zur umhüllung von medizinischen vorrichtungen |
EP1179353A1 (fr) * | 2000-08-11 | 2002-02-13 | B. Braun Melsungen Ag | Implants antithrombotiques avec un revêtement de polyphosphazène et d'un agent actif |
DE10100961B4 (de) | 2001-01-11 | 2005-08-04 | Polyzenix Gmbh | Körperverträglicher Werkstoff und mit diesem Werkstoff beschichtetes Substrat für die Züchtung von Zellen und künstlichen aus Zellen aufgebauten oder gewachsenen organischen Implantaten |
US9080146B2 (en) | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
WO2003015719A1 (fr) | 2001-08-17 | 2003-02-27 | Polyzenix Gmbh | Dispositif a base de nitinol comportant un revetement polyphosphate |
DE10107795B4 (de) * | 2001-02-13 | 2014-05-15 | Berlex Ag | Gefäßstütze mit einem Grundkörper, Verfahren zur Herstellung der Gefäßstütze, Vorrichtung zur Beschichtung der Gefäßstütze |
DE50210591D1 (de) | 2001-02-16 | 2007-09-13 | Abbott Lab Vascular Entpr Ltd | Implantate mit fk506 zur restenosebehandlung und -prophylaxe |
EP1270026A1 (fr) * | 2001-06-22 | 2003-01-02 | Erik Andersen | Stents comprenant des analogues de vitamine D pour éviter les resténoses |
DE10142881A1 (de) * | 2001-09-03 | 2003-04-03 | Jomed Gmbh | Implantate mit Combretastatin A-4 (CA4) |
SI1483251T1 (sl) | 2002-03-12 | 2010-03-31 | Bristol Myers Squibb Co | C cian epotilonski derivati |
DE10231336A1 (de) * | 2002-07-11 | 2004-01-22 | Bayer Ag | Stents |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1767535T3 (da) | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse |
CN1723018A (zh) * | 2002-12-09 | 2006-01-18 | 诺瓦提斯公司 | 用于治疗支架狭窄的微管稳定剂 |
US8318235B2 (en) | 2003-01-22 | 2012-11-27 | Cordis Corporation | Method for applying drug coating to a medical device in surgeon room |
US20050038504A1 (en) * | 2003-01-22 | 2005-02-17 | Harry Halleriet | Kit for applying drug coating to a medical device in surgeon room |
US9107850B2 (en) | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US9114162B2 (en) | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
ES2378905T3 (es) | 2006-10-10 | 2012-04-19 | Celonova Biosciences, Inc. | Válvula cardiaca bioprotésica con polifosfaceno |
EP2065054A1 (fr) * | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinaisons comprenant une prostaglandine et leurs utilisations |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3524451A1 (de) * | 1985-07-09 | 1987-03-12 | Behringwerke Ag | Mit ueberzuegen versehene formkoerper zur bindung von bioaffinen substanzen, verfahren zu ihrer herstellung sowie ihre verwendung |
US4758435A (en) * | 1986-08-11 | 1988-07-19 | American Cyanamid Company | Estradiol implant composition and method for preparation |
ES2054784T3 (es) * | 1987-08-08 | 1994-08-16 | Akzo Nv | Un metodo para la fabricacion de un implante. |
US4846844A (en) * | 1987-08-31 | 1989-07-11 | Eli Lilly And Company | Antimicrobial coated implants |
CH683673A5 (de) * | 1991-10-01 | 1994-04-29 | Otsuka Pharma Co Ltd | Antithromboseharz, Antithromboseröhrchen, Antithrombosefilm und Antithromboseüberzug. |
US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5886026A (en) * | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
ATE502664T1 (de) * | 1993-07-19 | 2011-04-15 | Angiotech Pharm Inc | Herstellungsmethode eines stents mit anti- angiogener zusammensetzung |
DE4334272C2 (de) * | 1993-10-07 | 1996-07-18 | Stemberger Axel Dr | Beschichtung für Biomaterial und seine Verwendung |
CN1304058C (zh) * | 1996-03-12 | 2007-03-14 | Pg-Txl有限公司 | 水溶性紫杉醇产品 |
CN1219872A (zh) * | 1996-05-24 | 1999-06-16 | 血管技术药物公司 | 治疗或预防身体通道疾病的组合物和方法 |
-
1997
- 1997-09-29 DE DE19744135A patent/DE19744135C1/de not_active Expired - Lifetime
-
1998
- 1998-09-24 WO PCT/EP1998/006019 patent/WO1999016416A2/fr not_active Application Discontinuation
- 1998-09-24 AU AU10251/99A patent/AU1025199A/en not_active Abandoned
- 1998-09-24 EP EP98952617A patent/EP1024842A2/fr not_active Withdrawn
- 1998-09-24 JP JP2000513554A patent/JP2001517543A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9916416A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU1025199A (en) | 1999-04-23 |
JP2001517543A (ja) | 2001-10-09 |
WO1999016416A2 (fr) | 1999-04-08 |
DE19744135C1 (de) | 1999-03-25 |
WO1999016416A3 (fr) | 1999-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19744135C1 (de) | Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe | |
DE69727777T2 (de) | Verfahren und Vorrichtung zum Anbringen medizinische Wirkstoffe freisetzender Beschichtungen | |
EP1562565B1 (fr) | Utilisation d'un ou de plusieurs elements du groupe rassemblant l'yttrium, le neodyme et le zirconium | |
EP0980274B1 (fr) | Tuteurs a revetement polymere, leurs procedes de fabrication et leur utilisation en prophylaxie de la restenose | |
EP1389471B1 (fr) | Procédé de préparation d'un stent implantable ayant un revêtement de poly-L-lactide de poids moléculaire élevé | |
EP2857048B1 (fr) | Dispositif médical d'administration de médicament | |
DE69637302T2 (de) | Verfahren zur Beschichtung von Arzneimittel enthaltenden Stents | |
DE60203265T2 (de) | Stents mit arzneimittelhaltigem amphiphilem polymerüberzug | |
DE602004010977T2 (de) | Herstellungsverfahren von einem Stent mit laminierter Arzneimittel-Polymerbeschichtung | |
EP2269664B1 (fr) | Produit médical pour le traitement de fermetures de passages de corps et de prévention des menaces de refermetures | |
EP1389472B1 (fr) | Implant endovasculaire avec un revêtement actif | |
DE19754870A1 (de) | Gefäßprothese | |
DE29724864U1 (de) | Stent-Beschichtung zur Freisetzung von Arzneimitteln | |
EP2033668A2 (fr) | Implant en alliage de magnésium biocorrodable et d'un revêtement en polyphosphazènes biocorrodables | |
EP2111880A2 (fr) | Stent métallique biodégradable | |
EP2070558A2 (fr) | Implants dotés d'une membrane permettant la diffusion contrôlée d'agent actif | |
EP2415489B1 (fr) | Implant revêtu d'agents polylactiques issu d'un alliage de magnésium biocorrodable | |
DE202009017490U1 (de) | Weihrauch- und/oder Boswelliasäuren Beschichtung | |
EP3613449A1 (fr) | Amélioration de la couche polymère dans des dispositifs dégradables | |
EP2462962B1 (fr) | Implant doté d'un revêtement comprenant un principe actif et recouvrant l'implant au moins partiellement | |
DE102013108870A1 (de) | Mittel zur Reinigung und zum Schutz von technischen Oberflächen | |
DE102019116791B4 (de) | Stent mit sofort ablösbarer Beschichtung | |
DE19713213A1 (de) | Metallstent zur verlängerten Offenhaltung von Hohlorganen | |
DE102014106422A1 (de) | Verfahren, Vorrichtung und Zusammensetzung zur Herstellung von beschichteten Ballonkathetern | |
DE10228078B3 (de) | Mittel zur Beschichtung von Implantaten sowie Verfahren zur Beschichtung von Implantaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000129 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20021126 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20030513 |